Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL
Status:
NOT_YET_RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
This trial is a prospective, single-center, randomized controlled clinical research. The intention is to evaluate the efficacy and safety of zanubrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients through prospective clinical studies.